Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability

Molecular Cancer Therapeutics

Volumn 9, Issue 10, 2010, Pages 2700-2713

  Oroudjev, Emin ^a   Lopus, Manu ^a   Wilson, Leslie ^a   Audette, Charlene ^b   Provenzano, Carmela ^b   Erickson, Hans ^b   Kovtun, Yelena ^b   Chari, Ravi ^b   Jordan, Mary Ann ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b IMMUNOGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC ALKALOID; DRUG METABOLITE; EPITHELIAL CELL ADHESION MOLECULE SMCC MAYTANSINOID DM1 ANTIBODY CONJUGATE; EPITHELIAL CELL ADHESION MOLECULE SSP MAYTANSINOID DM1 ANTIBODY CONJUGATE; MAYTANSINE; S METHYLMAYTANSINOID DM1; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; HUMAN; HUMAN CELL; IC 50; INTERNALIZATION; METAPHASE; MICROTUBULE; MICROTUBULE ASSEMBLY; MICROTUBULE DYNAMIC INSTABILITY; MITOSIS INHIBITION; MITOSIS SPINDLE; PRIORITY JOURNAL; PROMETAPHASE; TIME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; IMMUNOCONJUGATES; MAYTANSINE; MICROSCOPY, FLUORESCENCE; MICROTUBULES; MITOSIS;

EID: 77958059151     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0645     Document Type: Article

References (44)

1. Kupchan SM, Komoda Y, Branfman AR, et al. The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides. J Org Chem 1977;42:2349-57.
2. Kupchan SM, Komoda Y, Court WA, et al. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc 1972;94:1354-6.
3. Kupchan SM, Sneden AT, Branfman AR, et al. Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids. J Med Chem 1978;21:31-7.
4. Sieber SM, Wolpert MK, Adamson RH, Cysyk RL, Bono VH, Johns DG. Experimental studies with maytansine - a new antitumor agent. Bibl Haematol 1975:495-500.
5. Wolpert-DeFilippes MK, Bono VH, Jr., Dion RL, Johns DG. Initial studies on maytansine-induced metaphase arrest in L1210 murine leukemia cells. Biochem Pharmacol 1975;24:1735-8.
6. Bhattacharyya B, Wolff J. Maytansine binding to the vinblastine sites of tubulin. FEBS Lett 1977;75:159-62.
7. Mandelbaum-Shavit F, Wolpert-DeFilippes MK, Johns DG. Binding of maytansine to rat brain tubulin. Biochem Biophys Res Commun 1976;72:47-54.
8. Sieber SM, Mead JA, Adamson RH. Pharmacology of antitumor agents from higher plants. Cancer Treat Rep 1976;60:1127-39.
9. Remillard S, Rebhun LI, Howie GA, Kupchan SM. Antimitotic activity of the potent tumor inhibitor maytansine. Science (New York, NY) 1975;189:1002-5.
10. Huang AB, Lin CM, Hamel E. Maytansine inhibits nucleotide binding at the exchangeable site of tubulin. Biochem Biophys Res Commun 1985;128:1239-46.
11. Issell BF, Crooke ST. Maytansine. Cancer Treat Rev 1978;5:199-207.
12. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 2008;41:98-107.
13. Ricart AD, Tolcher AW. Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract 2007;4:245-55.
14. Kovtun YV, Goldmacher VS. Cell killing by antibody-drug conjugates. Cancer Lett 2007;255:232-40.
15. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nature Biotechnol 2005;23:1137-46.
16. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Current Opin Pharmacol 2005;5:543-9.
17. Chari RV, Martell BA, Gross JL, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992;52:127-31.
18. Liu C, Tadayoni BM, Bourret LA, et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci U S A 1996;93:8618-23.
19. Kovtun YV, Audette CA, Ye Y, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66:3214-21.
20. Tolcher AW, Ochoa L, Hammond LA, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003;21:211-22.
21. Tijink BM, Buter J, de Bree R, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 2006;12:6064-72.
22. Helft PR, Schilsky RL, Hoke FJ, et al. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res 2004;10:4363-8.
23. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:2698-704.
24. Smith SV. Technology evaluation: huN901-1, ImmunoGen. Curr Opin Mol Ther 2005;7:394-401.
25. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006;66:4426-33.
26. Erickson HK, Widdison WC, Mayo MF, et al. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 2010;21:84-92.
27. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nature Rev 2004;4:253-65.
28. Jordan MA, Kamath K. How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 2007;7:730-42.
29. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem 2002;2:1-17.
30. Lopus M, Oroudjev E, Wilson L, et al. Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules. Mol Cancer Ther 2010;9:2689-99.
31. Xie H, Audette C, Hoffee M, Lambert JM, Blattler WA. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-1), and its two components in mice. J Pharmacol Exp Ther 2004;308:1073-82.
32. Widdison WC, Wilhelm SD, Cavanagh EE, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006;49:4392-408.
33. Kamath K, Jordan MA. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. Cancer Res 2003;63:6026-31.
34. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
35. Kamath K, Okouneva T, Larson G, Panda D, Wilson L, Jordan MA. 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. Mol Cancer Ther 2006;5:2225-33.
36. Kamath K, Oroudjev E, Jordan MA. Determination of microtubule dynamic instability in living cells. In: Cassimeris L, Phong T, editors. Methods in cell biology. Philadelphia: Elsevier; 2010, p. 1-14.
37. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-90.
38. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 1991;51:2212-22.
39. Ngan VK, Bellman K, Hill BT, Wilson L, Jordan MA. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 2001;60:225-32.
40. Kovtun YV, Audette CA, Mayo MF, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 2010;70:2528-37.
41. Azarenko O, Okouneva T, Singletary KW, Jordan MA, Wilson L. Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane. Carcinogenesis 2008;29:2360-8.
42. Jordan MA, Wilson L. The use and action of drugs in analyzing mitosis. Methods in cell biology. Academic Press; 1999, p. 267-95.
43. Jordan MA, Wilson L. The use of drugs to study the role of microtubule assembly dynamics in living cells. In: Vallee R, editor. Molecular motors and the cytoskeleton, methods in enzymology. San Diego: Academic Press; 1998, p. 252-76.
44. Dimitrov A, Quesnoit M, Moutel S, Cantaloube I, Pous C, Perez F. Detection of GTP-tubulin conformation in vivo reveals a role for GTP remnants in microtubule rescues. Science (New York, NY) 2008;322:1353-6.